1. The role of hypoxia-induced long noncoding RNAs (lncRNAs) in tumorigenesis and metastasis
- Author
-
Pei-Hua Peng, Kou-Juey Wu, Kai-Wen Hsu, and Joseph Chieh-Yu Lai
- Subjects
0301 basic medicine ,Medicine (General) ,Carcinogenesis ,QH301-705.5 ,lncRNAs ,Review Article ,medicine.disease_cause ,Genome ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,R5-920 ,Neoplasms ,medicine ,Humans ,Epigenetics ,Epithelial–mesenchymal transition ,Neoplasm Metastasis ,Biology (General) ,Hypoxia ,biology ,General Medicine ,medicine.disease ,Chromatin ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,Histone ,Tumor progression ,030220 oncology & carcinogenesis ,biology.protein ,Cancer research ,RNA, Long Noncoding ,LncRNA RP11-390F4.3 - Abstract
Long noncoding RNAs (lncRNAs) are noncoding RNAs with length greater than 200 nt. The biological roles and mechanisms mediated by lncRNAs have been extensively investigated. Hypoxia is a proven microenvironmental factor that promotes solid tumor metastasis. Epithelial-mesenchymal transition (EMT) is one of the major mechanisms induced by hypoxia to contribute to metastasis. Many lncRNAs have been shown to be induced by hypoxia and their roles have been delineated. In this review, we focus on the hypoxia-inducible lncRNAs that interact with protein/protein complex and chromatin/epigenetic factors, and the mechanisms that contribute to metastasis. The role of a recently discovered lncRNA RP11-390F4.3 in hypoxia-induced EMT is discussed. Whole genome approaches to delineating the association between lncRNAs and histone modifications are discussed. Other topics related to hypoxia-induced tumor progression but require further investigation are also mentioned. The clinical significance and treatment strategy targeted against lncRNAs are discussed. The review aims to identify suitable lncRNA targets that may provide feasible therapeutic venues for hypoxia-involved cancers.
- Published
- 2021